CYP3A4 and COVID-19: More recently, this same principle was applied for the approved oral COVID-19 drug Paxlovid, containing the SARS-CoV2-targeting protease inhibitor nirmatrelvir (PF-07321332), which is rapidly degraded by CYP3A.